BDX Q1 2026 Earnings Call Summary

Summary of Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

Total Revenue: $5.3 billion, a 0.4% increase year-over-year.
New BDX Revenue Growth: 2.5%, with broad-based growth in key areas.
Adjusted Gross Margin: 53.4%, slightly down from the previous year due to tariffs but above expectations.
Adjusted EPS: $2.91, a decline of 15.2% year-over-year, primarily impacted by tariffs.
Free Cash Flow: $548 million, with a conversion rate of 66%, up from 59% in the prior year.
Shareholder Returns: Approximately $550 million returned, including $250 million in share buybacks.

2. Strategic Updates and Business Highlights

Segment Reorganization: BDX has transitioned to a new segment structure focusing on Medical Essentials, Connected Care, Biopharma Systems, Interventional, and Life Sciences.
Life Sciences Transaction: The merger with Waters was completed ahead of schedule, providing a $4 billion cash distribution—$2 billion earmarked for share repurchases and $2 billion for debt reduction.
Growth Platforms: Strong performance in biologic drug delivery, PureWick, advanced tissue regeneration, and pharmacy automation, with mid-single-digit growth across 90% of the portfolio.
Operational Excellence: Continued focus on productivity improvements, achieving an 8% increase in productivity in Q1.

3. Forward Guidance and Outlook

Fiscal 2026 Guidance: Expecting low single-digit revenue growth for New BDX, with Q2 revenue growth projected at approximately 2%.
Adjusted EPS Guidance: Estimated between $12.35 and $12.65, reflecting a 6% growth at the midpoint, factoring in tariff impacts.
Operational Stability: No expected ramp-up from Q1 to Q2, indicating a stable outlook for the remainder of the year.

4. Bad News, Challenges, or Points of Concern

Headwinds: Challenges in 10% of the portfolio, particularly in Alaris vaccines in China, which are experiencing market dynamics that are expected to persist.
Margin Pressures: Adjusted operating margin decreased by 240 basis points year-over-year due to tariffs and increased commercial investments.
Alaris Performance: Although gaining market share, Alaris is expected to remain a headwind in the near term due to ongoing remediation efforts.

5. Notable Q&A Insights

CFO Search: The search for a new CFO is ongoing, with a focus on continuity and financial discipline.
Market Dynamics: Stable pricing environment observed, with slight positive pricing outside of China, which is expected to improve as market conditions stabilize.
Growth Opportunities: Emphasis on high-growth areas such as pharmacy automation and biologics, with expectations for continued strong performance in these segments.
Commercial Strategy: Enhanced focus on commercial capabilities and sales force expansion to drive growth, with new compensation plans and tech stacks being implemented to improve sales effectiveness.

Overall, BDX reported a solid start to fiscal 2026, with a focus on strategic growth areas despite facing some headwinds. The completion of the Waters transaction marks a significant milestone, allowing BDX to concentrate on its core medtech operations.

BDX — Becton, Dickinson and Company